July 9, 2018
TOKYO - Nikon Corporation (Nikon) is pleased to announce its decision to acquire issued stock in Chuo Sangio Co. (President: Kazuo Kuwahara, Nishinomiya, Hyogo (hereinafter "Chuo Sangio")), an importer and distributor of ophthalmic equipment, and to enter into a stock transfer contract. Nikon will start proceedings for 100% acquisition of Chuo Sangio, and merge Chuo Sangio and Optos KK (President: Kenichi Kawabe , Minato-ku, Tokyo), a subsidiary of Nikon, with the goal of establishing Nikon Healthcare Japan on October 1, 2018.
In 2015, Nikon wholly acquired the UK's Optos plc. Optos is a global company in the field of retinal diagnostic imaging equipment, and produces and sells ultra-widefield retinal imaging equipment.
Chuo Sangio sells ophthalmic equipment, such as Optos products, and provides after-sales care and maintenance services to the Japanese market. Chuo Sangio has a broad sales network for ophthalmic equipment, including sales offices in major cities in Japan, and is highly acclaimed for its experience and knowledge acquired through the provision of products and support services.
Nikon will acquire Chuo Sangio, and merge the company with Optos KK to establish Nikon Healthcare Japan. Nikon will accelerate the improvement of Nikon group's sales system in Japan to maximize synergy for the provision of ophthalmic equipment such as Optos products and services. Nikon continuously strives for "a world without vision loss" and contributes to the improvement of QOL (quality of life) of people worldwide.
Company profile of Chuo Sangio
|Name||Chuo Sangio Co.|
|Head Office||4-7 Kagura-cho, Nishinomiya, Hyogo, Japan 662-0977|
|Description of business||Sale of ophthalmic equipment and provision of after-sales care and maintenance services|
|Stock type||Unlisted stock|
|Business relationship with the company concerned||No capital or personal relationship.|
The information is current as of the date of publication. It is subject to change without notice.